Drug-Eluting Stents: Benefits And Risks

“Drug-Eluting Stents: Benefits and Risks

Introduction

On this special occasion, we are happy to review interesting topics related to Drug-Eluting Stents: Benefits and Risks. Come on knit interesting information and provide new insights to readers.

Table of Content

1 Related Articles Drug-Eluting Stents: Benefits and Risks
2 Introduction
3

Drug-Eluting Stents: Benefits and Risks

Drug-Eluting Stents: Benefits And Risks

Coronary artery disease (CAD) is a widespread and life-threatening condition characterized by the buildup of plaque inside the coronary arteries, which supply blood to the heart. This plaque buildup, known as atherosclerosis, narrows the arteries, reducing blood flow to the heart muscle. If left untreated, CAD can lead to chest pain (angina), shortness of breath, heart attack, and even death.

Percutaneous coronary intervention (PCI), commonly known as angioplasty, is a minimally invasive procedure used to open blocked coronary arteries. During PCI, a cardiologist inserts a thin, flexible tube called a catheter into a blood vessel in the arm or groin and guides it to the blocked artery. A balloon at the tip of the catheter is then inflated to compress the plaque against the artery wall, widening the artery and restoring blood flow.

To help keep the artery open after angioplasty, a stent is typically placed in the artery. A stent is a small, expandable mesh tube that acts as a scaffold to support the artery wall and prevent it from collapsing or re-narrowing.

Types of Stents

There are two main types of stents:

Bare-Metal Stents (BMS): These stents are made of stainless steel or other metal alloys and do not have any coating or medication on them. BMS were the first type of stents used in PCI and are still used in certain situations.
Drug-Eluting Stents (DES): These stents are coated with medication that is slowly released over time to help prevent the artery from re-narrowing. The medication typically used in DES is an anti-proliferative drug that inhibits the growth of cells that can cause restenosis (re-narrowing of the artery).

Benefits of Drug-Eluting Stents

DES have revolutionized the treatment of CAD and have become the preferred type of stent used in PCI. The main benefit of DES is their ability to reduce the risk of restenosis compared to BMS.

Reduced Restenosis: Restenosis is the re-narrowing of the artery after angioplasty and stent placement. It occurs when cells in the artery wall proliferate and form new tissue that blocks the artery. DES significantly reduce the risk of restenosis by releasing medication that inhibits cell growth. Studies have shown that DES reduce the risk of restenosis by 50-70% compared to BMS.
Reduced Need for Repeat Procedures: Because DES reduce the risk of restenosis, they also reduce the need for repeat procedures, such as repeat angioplasty or bypass surgery. This can save patients from the risks and costs associated with additional procedures.
Improved Long-Term Outcomes: Studies have shown that DES are associated with improved long-term outcomes compared to BMS, including a lower risk of heart attack, stroke, and death.

Risks of Drug-Eluting Stents

While DES offer significant benefits, they also carry some risks.

Late Stent Thrombosis: Stent thrombosis is the formation of a blood clot inside the stent. It is a rare but serious complication that can lead to heart attack or death. Late stent thrombosis is stent thrombosis that occurs more than 30 days after stent placement. DES have been associated with a slightly higher risk of late stent thrombosis compared to BMS. This is because the medication released by DES can interfere with the body’s ability to form a protective layer of cells over the stent, which can make the stent more prone to blood clot formation.
Delayed Healing: The medication released by DES can also delay the healing of the artery wall. This can increase the risk of complications, such as bleeding and infection.
Allergic Reactions: Some patients may be allergic to the medication or the polymer coating used in DES. Allergic reactions can range from mild skin rashes to severe anaphylaxis.
Cost: DES are more expensive than BMS. The cost of a DES can be several times higher than the cost of a BMS.

Dual Antiplatelet Therapy (DAPT)

To reduce the risk of stent thrombosis, patients who receive DES are typically prescribed dual antiplatelet therapy (DAPT). DAPT involves taking two antiplatelet medications, typically aspirin and clopidogrel (Plavix), prasugrel (Effient), or ticagrelor (Brilinta), to prevent blood clots from forming.

The duration of DAPT depends on the type of stent used, the patient’s risk factors, and the specific clinical situation. In general, patients who receive DES are recommended to take DAPT for at least 6-12 months. Some patients may need to take DAPT for a longer period of time, while others may be able to stop DAPT sooner.

It is important for patients to take DAPT exactly as prescribed by their doctor. Stopping DAPT prematurely can significantly increase the risk of stent thrombosis.

Factors to Consider When Choosing a Stent

The decision of whether to use a DES or a BMS depends on a variety of factors, including:

Complexity of the Lesion: DES are generally preferred for more complex lesions, such as long lesions, small vessels, and lesions located in critical areas of the heart.
Patient’s Risk Factors: Patients who are at high risk of restenosis, such as those with diabetes or kidney disease, may benefit more from DES.
Patient’s Bleeding Risk: Patients who are at high risk of bleeding may be better suited for BMS, as they require a shorter duration of DAPT.
Cost: The cost of the stent is also a factor to consider, as DES are more expensive than BMS.
Patient Adherence: Patient adherence to DAPT is crucial. If a patient is unlikely to adhere to the prescribed DAPT regimen, a BMS might be a safer option.

Newer Generation Drug-Eluting Stents

Newer generation DES have been developed to address some of the limitations of earlier generation DES. These newer stents have thinner struts, more biocompatible polymers, and different drug elution profiles. Studies have shown that newer generation DES have a lower risk of stent thrombosis and improved long-term outcomes compared to earlier generation DES.

Bioabsorbable Stents

Bioabsorbable stents are a new type of stent that is made of materials that dissolve over time. These stents provide temporary support to the artery and then gradually disappear, leaving the artery free of any foreign material. Bioabsorbable stents have the potential to reduce the risk of late stent thrombosis and other long-term complications associated with permanent stents. However, bioabsorbable stents are still relatively new and are not yet widely used.

Conclusion

Drug-eluting stents have revolutionized the treatment of coronary artery disease. They offer significant benefits in terms of reduced restenosis and improved long-term outcomes. However, they also carry some risks, such as late stent thrombosis.

The decision of whether to use a DES or a BMS depends on a variety of factors, and it is important for patients to discuss the risks and benefits of each type of stent with their doctor. DAPT is crucial for preventing stent thrombosis, and patients must adhere to the prescribed DAPT regimen.

Newer generation DES and bioabsorbable stents are being developed to further improve the safety and effectiveness of stent therapy.

Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with your doctor to determine the best treatment option for your specific condition.

Drug-Eluting Stents: Benefits and Risks

fitlifedaily